We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
SpringWorks came to life with a clutch of drugs licensed from Pfizer, but won't rely on Pfizer’s shelves forever, with plans to boost its pipeline by partnering with other biopharmas and academic institutions.
Scientists from China, South Korea and the U.S. succeeded in safe correction of the gene mutation in early human embryos that results in hypertrophic cardiomyopathy by using CRISPR/Cas9 genome editing technique.